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Increased co-expression of genes 
harboring the damaging de novo 
mutations in Chinese schizophrenic 
patients during prenatal 
development
Qiang Wang1,2,*, Miaoxin Li3,*, Zhenxing Yang2,3, Xun Hu4, Hei-Man Wu3, Peiyan Ni2, 
Hongyan Ren1, Wei Deng1, Mingli Li1, Xiaohong Ma2, Wanjun Guo1, Liansheng Zhao2, 
Yingcheng Wang2, Bo Xiang1, Wei Lei1, Pak C Sham3 & Tao Li1,2
Schizophrenia is a heritable, heterogeneous common psychiatric disorder. In this study, we evaluated 
the hypothesis that de novo variants (DNVs) contribute to the pathogenesis of schizophrenia. We 
performed exome sequencing in Chinese patients (N = 45) with schizophrenia and their unaffected 
parents (N = 90). Forty genes were found to contain DNVs. These genes had enriched transcriptional 
co-expression profile in prenatal frontal cortex (Bonferroni corrected p < 9.1 × 10−3), and in prenatal 
temporal and parietal regions (Bonferroni corrected p < 0.03). Also, four prenatal anatomical 
subregions (VCF, MFC, OFC and ITC) have shown significant enrichment of connectedness in co-
expression networks. Moreover, four genes (LRP1, MACF1, DICER1 and ABCA2) harboring the damaging 
de novo mutations are strongly prioritized as susceptibility genes by multiple evidences. Our findings in 
Chinese schizophrenic patients indicate the pathogenic role of DNVs, supporting the hypothesis that 
schizophrenia is a neurodevelopmental disease.
Schizophrenia is a complex clinical syndrome, which is characterized by abnormal perception, thought process, 
disorganized speech and behavior. It affects about 1% of the population worldwide and is considered as a heritable, 
heterogeneous common psychiatric disorder1. Results from the largest genome-wide association study (GWAS) 
in 36,989 cases with schizophrenia and 113,075 controls have led to the identification of 108 common loci with 
small effect (OR < 1.4) for schizophrenia2. While confirming some of the key hypotheses on the pathogenesis of 
schizophrenia, such as neurotransmitter dysfunction, this study also demonstrated the previously unknown roles 
of biological pathways involved in the development of the disorder. However, it remains unclear as to why all the 
identified common variants represent only a modest portion of the overall heritability of schizophrenia3. One of the 
possibilities is that a considerable number of rare variants are ‘hidden’ across linkage disequilibrium (LD) blocks, 
which also contribute to the genetic risk for the disorder4. Thus, there is a probability of occurrence of multiple 
rare variants with minor allele frequency (MAF) < 1%, and the association of each of these with a potential effect 
on the risk of developing schizophrenia. These effects may accumulate to present the onset of schizophrenia.
To date, various de novo variants (DNVs) have been identified as contributors for a number of neurodevel-
opmental disorders, such as autism spectrum disease (ASD)5,6, mental retardation7, and schizophrenia8–11. The 
hypothesis of ‘common disease, rare variants’ is increasingly becoming as appealing as the ‘common disease, com-
mon variants’ hypothesis. However, while the contribution of rare DNVs has been unfolded in western population, 
it has not been reported in population in eastern countries. Therefore, it is important to explore the pathogenic 
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potential of DNVs and their genomic influence on schizophrenia in ancestrally independent samples. In addition, 
although schizophrenia is associated with heritability rate of as high as 80%12, a large fraction of the population is 
without a family history of the disease (sporadic cases). Therefore, Xu et al. investigated the relationship between 
copy number variants (CNVs) and family history in schizophrenia. They demonstrated that de novo copy number 
mutations were significantly associated with sporadic rather than familial patients with schizophrenia13. Moreover, 
the study indicated differences in genetic mechanism between patients with sporadic and familial schizophrenia, 
providing new insights into the role of de novo non-synonymous variants in schizophrenia. However, in a larger 
sample, Fromer et al. demonstrated that there was no difference in the rate of de novo mutations in patients with 
sporadic and familial schizophrenia14.
Recently, studies have also investigated whether there was a functional correlation between the fetal expression 
bias of the mutated genes and the neurodevelopmental impact of the corresponding mutations, which focused 
on genetic control of transcription in the brain areas especially the dorsolateral prefrontal cortex (DLPFC)8,11 
and hippocampus cortex (HIP)8 during the stages of neurodevelopment. Although these findings are promising, 
they have not been replicated in independent sample sets yet. In addition, previous studies have shown that the 
accrued risk of neurodevelopmental diseases, such as ASD15–18, intellectual disability19,20, and schizophrenia21 was 
associated with greater paternal age as the rate of DNVs disrupting the gene functions increases. However, it is 
still equivocal for schizophrenia because of its genetic heterogeneity and complexity of phenotypes. These issues 
need to be retested in different population as well.
In this study, we conducted the exome sequencing analysis in 45 schizophrenia-parent trios in order to provide 
evidence for the contribution of DNVs to the pathogenesis of schizophrenia. We assessed the potential pathogenic 
impact and functional characterization of genes harboring the damaging DNVs, and analyzed co-expression net-
work of these genes in different brain regions at different developmental stages Furthermore, we evaluated whether 
the genes harboring the damaging DNVs in schizophrenic patients enrolled in the current study were nominated 
by recent exome sequencing studies in schizophrenia8,11, and whether any of identified genes corresponded with 
the location of the 108 independent schizophrenia-associated loci in the most recent large-scale genome-wide 
association study (GWAS)2. Finally, we tested the association between the number of amalgamated DNVs and 
cognitive measurements (the anti-interference ability and execute functions) in patients with schizophrenia.
Results
De novo mutations identified by exome sequencing.  We completed exome sequencing in 45 Han 
Chinese schizophrenia-parent trios. Details are showed in Table S1. On an average, we obtained 7.97 Gb of map-
pable sequence data per individual after exome enrichment, targeting ~48.56 Mb from exons and their flank-
ing regions. Overall, 1.6% of the total genome was covered, which represented a fraction corresponding to the 
NCBI Consensus Coding Sequences database (CCDS). A median of read depth was obtained as 54X, which was 
higher than the estimated depth (33X)22 required for highly accurate downstream heterozygous variant detection. 
Additionally, 90.69% of the captured target exons were covered by high-quality genotype calls (10X) to ensure good 
detection sensitivity22. The relatedness, based on the called genotypes, was consistent with the kinship (Figure S1), 
thereby suggesting a good quality of the sequencing data.
After the QC of the called variants, 66 exon DNVs were initially identified in the 45 case-parent trios. Fifty-seven 
mutations were validated by subsequent Sanger sequencing, which included 47 DNVs (Table 1) and 10 synonymous 
variants (Table S2) in 39 case-parent trios. The ratio of non-synonymous variants to synonymous variants (NS:S) 
was 4.7:1, which was similar to that reported in previous studies23–26. There were no differences in the sequencing 
coverage between the trios with sporadic or familial cases, or between the patients with or without de novo events 
(Figure S2). The mutation rate of the de novo mutation in the captured exome was estimated to be 2.2 × 10−8 
mutations per base per generation in the total sample. Of the total DNVs, 45 DNVs were missense variants, and 
2 DNVs constituted a single base pair Indel. This Indel led to a coding frame shift at one of the isoforms of the 
TRMT112 and TMEM132A genes. Of the 47 DNVs, 26 and 21 DNVs occurred in sporadic and familial trios, 
respectively. The average point mutation rates were 1.7 × 10−8 and 3.3 × 10−8 mutations per base per generation in 
32 sporadic and 13 familial trios respectively. The distribution of DNVs in the 32 sporadic trios followed a Poisson 
distribution (p < 0.14; goodness of fit by likelihood ratio test, mean = 0.81 with 95% confidence interval (CI) [0.5, 
1.1]) (Figure S3). The DNVs in the 13 familial trios did not exhibit a Poisson distribution, which was probably 
attributed to inadequate sample size.
Prediction for pathogenic potential of DNVs. All the 47 validated DNVs were either absent or had a 
MAF (< 1%) in the reference databases (1000 Genomes Project, dbSNPv137, and NHLBI GO ESP6500). Forty 
DNVs in 40 different genes were predicted to be damaging, deleterious, or disease causing by at least one of the 
seven bioinformatics prediction algorithms (SIFT, Polyphen2_HDIV, Polyphen2_HVAR, LRT, MutationTaster, 
MutationAssessor, and FATHMM) (Table 1). To simplify the annotation, the 40 DNVs were called as damaging 
mutation throughout the paper unless otherwise specified, and genes with DNV were called as case genes.
Prediction for pathogenic potential of genes. We then investigated whether the 40 genes harboring 
the damaging DNVs exhibited pathogenic potentials according to several recent gene-level measurements, along 
with analyzing co-expression network of these genes in different brain regions at different developmental stages. 
Evidences from the recent largest GWAS2 and previous exome sequencing studies8,11 were also explored.
Haploinsufficieny, Recessive Probability and Residual Variation Intolerance Scores (RVIS) analysis.  
In this study, the average haploinsufficiency score of the 40 genes was 0.37, which was significantly larger than a 
random set of genes with the same size on the whole genome (empirical p = 0.04 using random sampling with-
out replacement). This significance suggests the 40 genes have larger pathogenic potential to cause a dominant 
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Chro-
mo-
some Position R/A Gene MaxAF
GeneFu-
ture SIFT Polyphen2_HDIV
Polyphen2_
HVAR LRT
Muta-
tion-
Taster
Muta-
tionAs-
sessor FATHMM
1 22021668 A/G USP48 . missense T B;B;B;B B;B;B;B N D N T;T
1 39827053 C/T MACF1 . missense D B;B;B;B B;B;B;B N D L T;T;T;T;T;T
1 91844691 C/T HFM1 . missense D P;D;D P;D;P U D M T;T
1 243319624 G/A CEP170 . missense . . . . D . .
2 9650202 G/A ADAM17 5.00E-04 missense T D;D D;D D D M D
2 74758135 T/G HTRA2 . missense D D;D;D;D D;D;D;D D D M D;D
2 179635385 T/C TTN . missense D D;D;D;D;D D;D;D;D;D . D L T;T;T;T;T
3 43121633 C/T GTDC2 5.00E-04 missense T D D D D M D;D
3 50211303 G/C SEMA3F . missense D P;P B;B D D L T;T;T;T;T;T
3 57335855 C/A DNAH12 . missense . . . . N H .
3 119462963 C/T MAATS1 3.83E-04 missense D D;D;D D;D;D D D M T
6 132207739 C/G ENPP1 . missense D D D D D M D
7 27140937 A/G HOXA2 . missense D D D D D H D
7 28547270 G/T CREB5 . missense D D D D D M T;T;T;T;T
7 121773654 C/T AASS . missense T P P D D N T;T
7 128658136 T/G TNPO3 . missense D D;D;D D;D;D D D M T;T;T;T
7 143657109 G/A OR2F1 . missense D D D D N H T
9 133952647 G/A LAMC3 . missense T D P N N L T
9 139907507 G/A ABCA2 1.23E-04 missense T B;B B;B U N N D;D;D
9 140147394 C/T C9orf173 . missense T B;P;P;B B;B;B;B N N N T;T
10 97763961 A/C CC2D2B . missense T . . . D . T
11 20119268 C/T NAV2 . missense . P;P;P;D P;B;P;B D D N T;T;T;T;T;T;T;T
11 61277216 C/T LRRC10B . missense T B B U N N T
11 68370926 G/C PPP6R3 . missense T D;B;P;D;D;D;D;P D;B;P;P;P;P;D;P D D L T;T;T;T;T;T;T;T;T;T;T
11 71943335 G/A INPPL1 . missense T D D D D M T;T;T
11 73103282 G/A RELT . missense D B B N N M T;T
11 130319553 T/G ADAMTS15 . missense D P P . D L T
12 21795009 G/A LDHB . missense D P P N D H D;D;D
12 57554800 A/G LRP1 . missense T D D D D M D
12 111885301 C/T SH2B3 . missense D D;D;D D;D;D D D M T;T
12 117187992 G/A RNFT2 . missense T P;P B;B D D L T;T
12 122261146 G/C SETD1B . missense T P B N N N D;D
14 95590756 G/A DICER1 . missense D D P D D L T;T;T;T;T
14 103465975 C/T CDC42BPB . missense D P P D D L T
15 45694835 G/A SPATA5L1 . missense T D P D D M D
15 49584699 T/A GALK2 . missense D D;D D;D D D M D;T;D
16 12798895 G/A CPPED1 . missense D D D D D M D
16 89350182 T/C ANKRD11 . missense T B;B B;B N D L T;T
17 67302892 T/C ABCA5 . missense . B;P B;B D D N D;D
17 80146156 G/A CCDC57 . missense T D;D D;D D D M T;T;T
1 152191073 C/T HRNR . missense T B B . N N T
6 42074959 C/T C6orf132 . missense T . . . N N T
6 46660790 C/T TDRD6 . missense T B;B B;B N N L T;T
11 60703710 CG/C- TMEM132A . frameshift . . . . . . .
11 64084952 A/+ C TRMT112 . frameshift . . . . . . .
12 21175888 A/C SLCO1B7 . missense T B;B B;B N N N T;T;T
20 3674309 C/T SIGLEC1 0.009304 missense T B;B B;B N N N T;T
Table 1.  The predicted functions of the 47 validated de novo non-synonymous variants used 7 
bioinformatics tool. R/A: Reference/Alternative alleles; Missing value;MaxAF: maximal alterative allele 
frequency; SIFT T: tolerated; SIFT D: damaging; Polyphen2B: benign; Polyphen2 D: probably damaging; 
Polyphen2P:possibly damaging mutation; LRT D: Deleterious; LRT N: neutral;LRT U:unknown; 
MutationTasterD disease_causing; MutationTasterN: polymorphism; MutationAssessorH: highfunctional 
impact; MutationAssessor M: medium functional impact; MutationAssessor L: low functional impact; 
MutationAssessor N: neutral functional impact; FATHMM D: damaging; FATHMM T: tolerated.
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disease27. Their average recessive probability was not significantly different from a random set of genes (empirical 
p = 0.07 using random sampling without replacement), which suggests many of these genes are unlikely to cause 
a recessive disease. This pattern is consistent with our hypothetic inheritance model (dominant model)28. Their 
average RVIS (− 0.75 and − 0.6, which were derived from 0.1% or 1% variants in the ESP6500 sample respectively) 
were significantly smaller than the random set of the same size (p < 3.4 × 10−6 and 1.7 × 10−4, respectively, using 
the same random sampling approach)29 (Table S3), suggesting that these genes are less tolerant to mutations and 
are more likely to be pathogenic.
Brain-critical-exon gene enrichment analysis. Among the 40 genes harboring the damaging DNVs, 
eight genes (ABCA2, CDC42BPB, USP48, MACF1, CEP170, NAV2, RNFT2, and DICER1) were enriched for 
‘Brain-critical exons’, which are highly expressed in human brain under strict purifying selection30. According to 
hypergeometric distribution test, these eight genes were overrepresented (p < 0.026) in a list of 1744 genes enriched 
with ‘brain-critical exons’ by Uddin et al.30. The ABCA2 gene exhibited the highest exon score, 5.73. The significant 
enrichment within ‘Brain-Critical Exons’ also implicates the pathogenic potential of these genes to schizophrenia.
Co-expression of genes harboring de novo mutations in different brain regions at different devel-
opmental stages. Inspired by Gulsuner et al.11 we subsequently determined whether the 40 genes exhib-
ited significant co-expression in four brain regions (frontal cortex, temporal and parietal regions, sensory-motor 
regions, and subcortical regions) at three developmental stages (prenatal, infancy to late childhood, and adoles-
cence to adulthood) using RNA-Seq data in the BrainSpan Atlas (Table S4). In the prenatal frontal cortex, the 40 
genes harbouring the predicted damaging DNVs in patients showed substantially higher degree of co-expression 
(r ≥ 0.8) as compared to random gene set, matched for gene size from 240 genes harbouring the DNVs (nominal 
p < 8.0 × 10−4; Bonferroni correction for multiple comparisons, p < 9.1 × 10−3; Fig. 1). This finding was consist-
ent with the results reported by Gulsuner et al.11, although none of the genes harbouring the DNVs overlapped 
between these two studies. In addition, we also identified a new significant relatedness in the genes that har-
bour the damaging DNVs (case genes), in the prenatal temporal and parietal regions (nominal p < 2.7 × 10−3; 
Bonferroni correction for multiple comparisons, p < 0.03), which was not significant in the study of Gulsuner et 
al.11 Consistent with Gulsuner et al. no other regions or developmental stages exhibited significant relatedness in 
the co-expression networks. Moreover, co-expression among the five genes harbouring de novo benign mutations 
in the schizophrenia trios was not observed.
In the subsequent analysis, we further examined the enrichment for relatedness of the 40 genes in co-expression 
networks at seven specific anatomical subregions of the prenatal frontal cortex and temporal-parietal regions, 
including the dorsolateral prefrontal cortex (DFC), anterior (rostral) cingulate (medial prefrontal) cortex (MFC), 
orbital frontal cortex (OFC), ventrolateral prefrontal cortex (VFC), inferolateral temporal cortex (area TEv, area 
20) (ITC), posterior (caudal) superior temporal cortex (area TAc) (STC), and posteroinferior (ventral) parietal 
cortex (IPC). In accordance with Gulsuner et al.11, the VFC exhibited significantly greater relatedness in the 
co-expression network as compared to the genes which do not harbour the damaging DNVs (control genes) 
(nominal p < 4.0 × 10−3; Bonferroni correction for multiple comparisons, p < 0.048; Table 2 and Fig. 1). Moreover, 
three subregions (MFC, OFC, and ITC) exhibited significant enrichment of the relatedness in the co-expression 
networks, i.e., the corrected p for multiple comparisons by Bonferroni method was < 0.05. Interestingly, after 
merging the four networks, all the co-expression pairs were connected in a single network, which contained 28 
genes (Fig. 2). In the merged network, nine genes (NAV2, CDC42BPB, ANKRD11, SETD1B, MACF1, ANKRD11, 
RNFT2, LRP1, and ABCA2) were highly inter-connected with positive co-expression (r ≥ 0.8; Fig. 2). In addition, 
six genes (ABCA2, ANKRD11, ANKRD11, CDC42BPB, RNFT2, and LRP1) exhibited nine or more connections 
with other genes (Fig. 2).
Furthermore, we demonstrated that of the total 40 genes, excluding two genes lacking expression data in the 
frontal and temporal cortices, most of the genes exhibited high expression levels in brain in early foetal develop-
ment, decreased expression at the end of foetal development and during childhood, and an increase in expression 
during early adulthood. The expression levels of individual network genes in the foetal frontal and temporal cortices 
are provided in Figures S4 and S5.
Constrained gene analysis. A statistical measurement, constrained gene score, was recently proposed to 
evaluate excesses of de novo mutations in a gene for human diseases31. Subsequently, we asked whether the genes 
with damaging de novo mutations identified in present study are significantly enriched in a list of constrained genes 
from Kaitlin et al.31. Among the 40 genes, 8 genes (LRP1, ABCA2, CEP170, HTRA2, DICER1, MACF1, ADAMTS15 
and SEMA3F) occurred in the top 1000 constrained gene list (p = 9.8 × 10−4, hypergeometric test based on 18,988 
CCDS protein coding genes) (Table S3), suggesting it is unlikely that these genes harbor de novo mutations only by 
chance in our schizophrenic patients, and the occurrence of de novo mutations may be related to schizophrenia. 
Interestingly, among 8 constrained genes, the top gene LRP1 has significant positive co-expression with the second 
gene ABCA2 in MFC, OFC and ITC. The LRP1 also has significant positive co-expression with a constrained gene 
MACF1 in VFC and ITC, and in merged co-expression network. In addition, the third constrained gene CEP170 
has significance positive co-expression with DICER1 in MFC and OFC (Fig. 2). Finally, the DICER1 exhibited a 
significant negative co-expression with HTRA2 in OFC.
Genes in previous studies on de novo mutations of schizophrenia. We also assessed which of the 
40 genes harboured DNVs in the schizophrenic patients were included in five recent exome sequencing studies 
using a hypergeometric test based on 19,043 known protein coding genes and 733 involved genes. There were four 
overlapping genes, including LRP1, MACF1, DICER1, and TTN (a marginally significant over-representation, 
p < 0.067). LRP1 was reported to harbour a stop-gain DNV at c.C6600A16. MACF1 was reported to harbour a 
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Figure 1. Relatedness of 40 genes in the co-expression network in four brain regions at three 
developmental stages. We evaluated the co-expression of genes harboring the damaging DNVs in cases and 
controls using RNA-seq data from the BrainSpan Atlas. Gene pairs were defined as co-expressed if Spearman’s 
rank correlation coefficient ( |R| )> 0.8 for RNA-seq expression levels across different brain areas and a given 
developmental stage. Networks were created for co-expressed gene pairs as described for Fig. 2. Histograms 
represent distributions of the numbers of edges in 100,000 simulated networks using genes harboring 
the damaging DNVs in controls. Dotted lines indicate the numbers of connections (edges) in networks 
created using genes harboring the damaging DNVs in cases with schizophrenia. The significant enrichment 
in co-expression of gene mutants in schizophrenia was observed in the frontal cortex and temporal and 
parietal regions during prenatal development (p < 0.0091 and 0.03 after Bonferroni corrections for multiple 
comparisons) at prenatal stage. There was no enrichment of co-expression of genes harboring the damaging 
DNVs at the other stages.
Prenatal Infancy to late childhood Adolescence to adulthood
#Node #Connection(p-value) #Node #Connection(p-value) #Node #Connection(p-value)
Medial prefrontal cortex (MFC) 24 23 (0.003) 20 21 (0.817) 26 40 (0.706)
Ventrolateral prefrontal cortex(VFC) 18 30 (0.004) 23 37 (0.303) 31 48 (0.477)
Orbital frontal cortex(OFC) 20 29 (0.001) 21 21 (0.465) 27 44 (0.266)
Inferolateral temporal cortex (ITC) 25 31 (0.001) 15 10 (0.853) 26 47 (0.478)
Table 2.  Analysis of networks of 40 genes with predicted damaging DNVs in co-expression networks of 
four brain regions at three developmental stages. The p-values were estimated from 100,000 random samples 
in the controls gene set.
www.nature.com/scientificreports/
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DNV at c.C12097T14; and the DNV detected in the present study was located at c.C6289T of the MACF1 transcript 
NM_012090. DICER1 was reported to harbour a damaging DNV at c.A1126G32, and this gene also contained a 
damaging DNV at c.C1153T. Given its large length in the exon region (> 100 kb), TTN may not be an interest-
ing candidate as compared to the other three genes. Nevertheless, this gene was reported to harbour DNVs at 
c.C7061T32 and c.A8134G according to the present study. Interestingly, in the above brain subregions of VFC and 
ITC, merged co-expression network (Fig. 2), both LRP1 and MACF1 demonstrated a high co-expression (r > 0.89).
Overlapped genes with large-scale GWAS.  We evaluated whether the genes harbouring the damaging 
de novo mutations also corresponded with the location of any of the 108 independent schizophrenia-associated 
loci in the most recent large-scale GWAS2. The LRP1 gene was located at the 20th genetic loci (chr12:57428314-
57682971), and was the only gene of the total 11 candidate genes in this ~250 kb region. Further studies are required 
to validate its pathogenic contribution to schizophrenia.
Integrated evidences for pathogenic prediction of genes with DNVs. Overall, we ranked 40 genes 
according to the numbers of supporting evidences as described above and 8 genes showed more than two sup-
porting evidences (Table S5). On the top of the list, both LRP1 and MACF1 genes are supported by 5 out of 6 
independent evidences, suggesting their high pathogenic potential for schizophrenia. Both genes are more likely 
to be pathogenic as they are less tolerant to mutations (RVIS), are in excess of de novo mutations (constrained 
gene score), and are hub genes in brain specific co-expression network that are highly connected with other 
genes. Both genes are also reported in previous de novo mutation studies in schizophrenia9,11. In addition, the 
MACF1 gene is enriched significantly within brain specific critical exons, and the LRP1 gene ranked top 20 in list 
of schizophrenia-associated loci in the recent large-scale GWAS2.
Pathway analysis of genes carrying de novo damaging mutations. In Gene ontology (GO) anno-
tation, we observed that eight GO terms (GO:0005524, GO:0000166, GO:0007163, GO:0006796, GO:0004386, 
GO:0016887, GO:0005911, and GO:0051015) were significantly overrepresented with some of the 40 genes with 
damaging DNVs (Bonferroni corrected p ≤ 0.05, hypergeometric distribution test; Figure S6). Moreover, physical 
interaction between MACF1 and DISC1 was detected using geneMANIA (http://www.genemania.org/) analysis, 
Figure 2. Co-expression networks of four significant subregions in prenatal brain. Each node indicates 
a gene and each edge denotes a co-expression between a pair of genes. A red edge denotes a positive co-
expression, whereas the green edge denotes a negative co-expression. Genes marked in yellow are reported 
to harbor the damaging DNVs in schizophrenia patients in previous studies. The dashed gray ellipse labels a 
clique in which the genes are highly connected. ITC: Inferolateral temporal cortex (area TEv, area 20); Merged: 
Merged network of the four networks; OFC: Orbital frontal cortex; MFC: Anterior (rostral) cingulate (medial 
prefrontal) cortex; and VFC: Ventrolateral prefrontal cortex.
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where both genes were associated with microtubule-based processes (p < 9.04 × 10–5). Additional details are 
provided in Figure S6.
Relationship between the amalgamated DNVs and cognitive function. We also examined the 
relationship between the amalgamated DNVs and cognitive measurements in schizophrenic patients using a linear 
regression model. Interestingly, although the association test was generally underpowered due to the small sample, 
three cognitive measurements [completion time obtained from the Stroop colour test and Stroop colour-word test 
and perseverative errors obtained from the Modified Wisconsin Card Sorting Test (WCST-M)], which assessed 
the anti-interference ability and executive functions of the patients with schizophrenia, showed promising asso-
ciations with p values of 0.0455, 0.00995 and 0.0301, respectively. The patients with more DNVs showed worse 
performance in anti-interference ability and executive function and details were showed in Figure S7; however, 
these associations must be validated in larger independent samples.
Discussion
To our knowledge, this is among the first exome sequencing study of schizophrenia in Han Chinese population. 
Firstly, by analyzing the genomic features, we found that 40 genes harboring the predicted damaging DNVs 
exhibited pathogenic potentials, which were supported by multiple gene-level assessments, and some of genes 
were also identified by the recent largest GWAS2 and previous exome sequencing studies9,11. Secondly, we found 
that the 40 genes harbouring the damaging DNVs in patients showed substantially higher degree of co-expression 
the prenatal frontal cortex, and in the prenatal temporal and parietal regions. Most of the genes exhibited high 
expression levels in brain in early foetal development, decreased expression at the end of foetal development and 
during childhood, and an increase in expression during early adulthood. Finally, we reported that the patients 
with more amalgamated DNVs showed worse performance in anti-interference ability and executive function in 
a preliminary analysis. The main findings are summarized in Fig. 3.
Of 8 genes showing more than two supporting evidences for pathogenic prediction, some of genes (e.g. LRP1, 
MACF1, DICER1 and ABCA2) harbours de novo mutations provided promising evidence as a strong candi-
date genes for schizophrenia. The ABCA2 is a hub gene in the co-expression network of prenatal frontal cortex. 
Importantly, three of these genes (LRP1, MACF1, and DICER1) were found to overlap with the genes associated 
with schizophrenia in previous studies10,33–35. LRP1 binds to neuroserpin and is involved in both serpin internal-
ization and signal transduction. Moreover, neuroserpin expression is up-regulated in a novel in vitro model of 
schizophrenia36. Study on induced pluripotent stem cell neuron, derived from patients with schizophrenia, has 
demonstrated a 5.6-fold increase in the neuroserpin expression as compared to matched controls, while decreased 
neuronal connectivity was associated with reduced dendritic arborization and impaired synaptic maturation as 
reported in vivo37,38.
In this study, we found that the genes with damaging DNVs enrich in co-expression networks of prenatal frontal 
and temporal cortex. Our findings also demonstrated that, in determining the risk of genes for schizophrenia, 
not only the tissue where the mutated genes express, but also the time when genes expressed may be of critical 
importance. This result confirms the findings by Xu et al.8 and Gulsuner et al.11, and supports a spatial and temporal 
pattern of DNVs in schizophrenia in ancestrally different samples with different set of genes. Xu et al. reported 
that the damaging DNVs in probands with schizophrenia enriched in a network of genes co-expressed in fetal 
hippocampus and dorsolateral prefrontal cortex14. Gulsuner et al. demonstrated damaging DNVs in probands 
with schizophrenia converged in a network of genes co-expressed in the dorsolateraland ventrolateral prefrontal 
cortex during fetal development11. In addition, we provided preliminary evidence that the genes harboring the 
DNVs might participate in worsening of neurocognitive performances, such as anti-interference and executive 
functions. All of these finding supported the hypothesis that disruptions of some vital brain regions at prenatal 
stage during neurogenesis are critical to the pathophysiological mechanisms of schizophrenia, and the disruption 
of gene function in some of the brain regions in prenatal stage might contribute to the development of this neu-
rodevelopmental disorder.
Previous studies have showed that anatomical and functional abnormity of prefrontal39,40, temporal cortex41–43, 
and frontal-subcortical circuit32,44–46 are involved in the pathogenesis of schizophrenia. Orbitofrontal circuit lesions 
characterized by disinhibition lead to personality changes, and anterior cingulate circuit lesions are associated with 
apathy of schizophrenia47. It is well known that prefrontal cortical network managed inputs from the other cortical 
and subcortical brain regions and have an important role in planning and directing motor activities, affection, 
neurocognition, and social behavior48. Ford et al. suggested that reduced fronto-temporal functional connectiv-
ity may contribute to the misattribution of the inner thoughts to external voices in schizophrenia49. In addition, 
besides the mesolimbic DA system, cortical DA system was found to play an important role in schizophrenia45. 
The growing evidence has showed that the neurodevelopment deficiencies in amygdala-prefrontal cortical circuit 
may lead to the dysregulation of DAergic modulation of emotional processing and learning, which contributes 
to the pathogenic mechanisms of schizophrenia32. Furthermore, a variety of cellular pathological findings in 
frontal-cortical tissue were observed during the postmortem of brain in schizophrenia patients50. In keeping with 
previous studies, our study supports that the fronto-temporal-subcortical circuit dysfunction is associated with 
the development of schizophrenia, which may be partly due to the presence of DNVs in genes as detected in this 
study. Four out of the nine genes (NAV2, CDC42BPB, MACF1, and LRP1) involved in co-expression network have 
considerable evidence for their pathogenic roles in the development of schizophrenia33,34,51,52. NAV2 (Neuronal 
Navigators 2) gene encodes a member of the neuron navigator gene family, and may play a role in cellular growth 
and migration. In previous studies, the expression of NAV2 gene was found to be associated with actin cytoskeleton 
remodeling53 and was down-regulated in schizophrenia54.
GO terms, which were largely related to the biological function and process especially during the early devel-
opmental stages, were significantly enriched with some of the 40 genes with damaging DNVs in pathway analysis 
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of the present study. GO:0051015 bears some resemblance with the category (GO:0051017) found in a previous 
DNVs study14. Both pathways act on the actin filament, which is highly enriched in dendritic spine55 and preserve 
cytoskeleton wholeness during cell development and migration56.
Some limitations, such as small sample size and lack of normal controls, should be also addressed in this 
study. We exploited existing data in the public domains to overcome the potential small-sample-size limitation 
of the current study. Making use of public control data, we demonstrated a significant co-expression pattern of 
our damaging DNVs genes in prenatal brains. This is highly consistent with two recent studies1,12 although few 
of involved genes are identical. Moreover, a number of genes in present study are also supported significantly 
by genomic features (for example genes’ mutation constraint37, RVIS36 and critical exon enrichment38). While a 
larger sample is preferable for schizophrenia study, we believe that the current sample revealed a few important 
susceptibility genes of schizophrenia. This cost-effective strategy should be encouraged so that more redisposing 
variants can be identified for schizophrenia.
Figure 3. Abstract plot of main findings of the study. (a) Circos imaging showing human chromosome 
ideogram with data tracks for gene labels and their expressional level in different developmental stages, which 
were transformed with log2(value) + 9 in four brain regions (MFC,OFC,VFC, and ITC), (b) Heatmap showing 
the above four brain regions in three developmental stages and their corresponding p values in co-expression 
network analyses.
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Taken together, our findings in Chinese schizophrenic patients reinforced the pathogenic role of DNVs, par-
ticularly in prefrontal, temporal cortex, and frontal-subcortical circuit during the early developmental stages of 
schizophrenia. Genetic and clinical heterogeneity provide a challenge for population-based association approaches 
and may require a more precise definition of phenotypes in the mapping of risk genes, especially regarding the 
improvements in brain function.
Material and Methods
Participants. Details of the participants and clinical assessment procedure are shown in supplementary doc-
ument and in Table S6. Written informed consent was obtained from all the participants and legal guardian. 
The study was approved by the ethical committee of West China Hospital of Sichuan University, China. And the 
methods were carried out in accordance with the approved guidelines.
Exome sequencing.  Genomic deoxyribonucleic acid (DNA) was purified from peripheral blood leucocytes. 
Deoxyribonucleic acid sample was prepared according to the Illumina Paired-End Sample Preparation Guide 
(http://supportres.illumina.com/documents/myillumina/e5af4eb5-6742-40c8-bcb1-d8b350bcb964/paired-end_
sampleprep_guide_1005063_e.pdf). Targeted enrichment was performed using TruSeq Exome Enrichment Kit 
(Illumina, San Diego, CA, USA), optimized for Illumina sequencing. Exon-enriched DNA libraries from 135 
subjects were individually sequenced on an IlluminaHiSeq2000 at Axeq Technologies (http://www.axeq.com/), 
which produced 101 base paired-end reads, in accordance with the manufacturer’s instructions.
Data processing and variant calling. The pipeline for exome data analysis is described in Figure S8. Briefly, 
sequencing reads were initially mapped to University of California, Santa Cruz (UCSC) human reference genome 
(hg19) using Burrows-Wheeler Alignment tool (BWA)57. Duplicate reads were flagged and removed by Picard-tools 
(http://picard.sourceforge.net/). The Genome Analysis Toolkit (GATK, version 2.3)58 was then used for realignment 
of the reads around the insertion/deletion (Indel) sites and base quality recalibration. Finally, the GATK was used 
to detect single nucleotide variants (SNVs) and short Indels from all the trios simultaneously. Variants’ quality 
assessment (QA) and quality control (QC) were performed on raw and clean variant set repeatedly to make sure 
the calling process was well performed, otherwise the whole calling process was subjected to revision. Concrete 
criteria in QA include total number of variants, dbSNP coverage, and transition/transversion (Ti/Tv) ratio. The 
variants’ quality score recalibration (VQSR) was used for QC. Meanwhile, these variants’ sets were also used to 
examine sample relatedness in PLINK for quality assessment59. KGGSeq (http://statgenpro.psychiatry.hku.hk/
kggseq/) was used to extract de novo SNVs and Indels with standard QC based on the levels of genotype and vari-
ants. Genotypes with Phred-scaled quality score of < 30, depth < 10X, ≥ 5% alternative allele supporting reference 
homozygous genotypes, ≤ 25% and 70% alternative allele supporting heterozygous and alternative homozygous 
genotypes respectively were eliminated. Variants with Phred-scaled sequencing quality of < 50, mapping quality 
< 20, strand bias > 60, call rate < 60% and Hardy-Weinberg equilibrium test p < 0.00001 were also excluded. A 
DNV was called as a variant, which was present in the proband, but absent in either of the parents. The DNVs 
identified using exome sequencing were validated using standard Sanger sequencing on ABI 3730xl DNA Analyzer 
by designing custom primers (Sigma) based on ~500 bp of genomic sequence, flanking each variant.
Annotation of de novo variants. KGGSeq60 was also used to map the extracted DNVs systematically. The 
variants were mapped into genes according to three gene definitions (RefGene, KnownGene, and GEncode). 
Alternative allele frequencies from 1000 Genome Project61 and NHLBI Grand Opportunity Exome Sequencing 
Project were used to annotate the de novo variants. A variant was regarded as a non-synonymous mutation as long as 
it was defined by one of the gene definitions. The non-synonymous variant was annotated for its protein damming 
or deleteriousness potential by seven in silico prediction algorithms (SIFT, Polyphen2_HDIV, Polyphen2_HVAR, 
LRT, MutationTaster, MutationAssessor, and FATHMM) originally collected in dbNSFP2.462. Papers from National 
Center for Biotechnology Information (NCBI) PubMed database (http://www.ncbi.nlm.nih.gov/pubmed/), which 
mentioned a gene harboring interested DNVs and schizophrenia in the title or abstract, were also retrieved auto-
matically by KGGSeq.
Evaluation of statistical significance for a set of genes.  We wrote a java program to assess the statistical 
significance of a measurement for a set of m case genes, harboring DNVs, and compared them to a set of n control 
genes ( n m). Based on an interested measurement (e.g., pathogenic scores and network connections) as an 
absolved value, a statistical value, such as mean or summation was first calculated for the case genes. In the control 
gene set, t genes sets with size m were randomly sampled without replacement using a random engine in a java 
package, Colt (http://acs.lbl.gov/ACSSoftware/colt). The same statistical value was calculated for the t random 
gene sets. The number of sets with a statistical value of over or equal to the observed value was represented as s. 
The empirical p value was estimated as (s + 1)/(t + 1).
Pathogenic analysis of genes. Three in silico scores (haploinsufficiency27, recessive probability28, and genic 
intolerance29) were employed to accesses the pathogenic impact of genes. The haploinsufficiency and recessive 
probability scores were downloaded from dbNSFP V2.462. The genic intolerance scores (based on all ESP6500 
samples) were downloaded from http://chgv.org/GenicIntolerance/. The significance of these scores for a set of 
genes harboring interesting DNVs were evaluated by the random sampling approaches as mentioned above.
Brain-critical-exon gene enrichment analysis. The 1744 genes enriched with ‘brain-critical exons’ were 
downloaded from the supplementary Table 7 of Uddin et al.30 to assess the contribution of genes harboring the 
damaging DNVs. Hypergeometric distribution was used to evaluate the statistical significance of enrichment using 
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our R package (http://www.r-project.org/). In addition, the critical exon-scores of genes in this table were used to 
prioritize genes with damaging DNVs.
Constrained genes analysis. We downloaded the top 1003 constrained genes, which were specifically pro-
vided to evaluate excesses of de novo mutations in a gene for human diseases. In the NHLBI Grand Opportunity 
Exome Sequencing Project (ESP) sample, which contained about 6500 individuals, these genes tend to have less 
rare missense variants than the expected, suggesting strong purifying selection in human population. We checked 
whether the top constrained genes were enriched in our genes harboring de novo mutations by the hypergeometric 
distribution test.
Gene ontology (GO) annotation.  To characterize the functions of genes harboring the damaging DNVs, 
the gene set enrichment analysis (GSEA) on GO was performed under a hypergeometric distribution on R package 
(http://www.r-project.org/). The GO surviving Bonferroni correction (p < 0.05) was regarded as significant. The 
GO gene sets were obtained from NCBI (ftp://ftp.ncbi.nlm.nih.gov/gene/DATA/gene2go.gz) and the pathway gene 
sets from Pathway Interaction Database (PID) (http://pid.nci.nih.gov/).
Co-expression network analysis. The standardized gene expression data in 26 brain subregions at multiple 
developmental stages were downloaded from BrainSpan (http://www.brainspan.org). Four regions (frontal cortex, 
temporal and parietal regions, sensory-motor regions, and subcortical regions), which include 11 subregions, 
were selected for co-expression analysis at three developmental stages: (1) prenatal stage: 8–37 post conception 
weeks (PCW); (2) infancy to late childhood: 4 months to11 years; and (3) adolescence to adulthood: 13–23 years 
according to Gulsuner et al.11 (Table S4).
A co-expression network was built for each of the brain regions at different developmental stages. Given the 
expression values for a pair of genes, Spearman’s rank correlation coefficient (r) was calculated to measure the level 
of co-expression of paired genes. Similar to Gulsuner et al.11 we used a cutoff point (r = 0.8) to exclude the genes 
with relatively low co-expression levels. The retained co-expression gene pairs were used to form a co-expression 
network. The above random sampling approach was used to evaluate the statistical significance of interconnect-
edness for non-interested case gene set by counting the connections, or edges36, as compared to 240 control genes 
harboring the damaging DNVs in healthy subjects11. Cytoscape 3.0.163 was used to visualize and plot the network.
Statistical analysis. The Kolmogorov-Smirnov test (KS-test) was used to compare the distribution of pre-
diction scores among DNVs. Fisher’s exact test or Chi-square test with Yates’ correction was used for the analysis 
of contingency tables depending on the sample sizes. We examined the relationship between the number of DNVs 
and cognitive measurements using a linear regression model. All statistical analysis was conducted using R64.
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